Trial Profile
Single-centre study to investigate the relationship between discontinuation of sunatinib or pazopanib and flare-ups in metastatic renal cell carcinoma patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Dec 2015
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 16 Dec 2015 New trial record